- Home
- IONS vs CMC Comparison
IONS vs CMC Comparison
Compare IONS & CMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CMC
- Stock Information
- Founded
- IONS 1989
- CMC 1915
- Country
- IONS United States
- CMC United States
- Employees
- IONS N/A
- CMC N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CMC Steel/Iron Ore
- Sector
- IONS Health Care
- CMC Industrials
- Exchange
- IONS Nasdaq
- CMC Nasdaq
- Market Cap
- IONS 4.6B
- CMC 4.9B
- IPO Year
- IONS 1991
- CMC 1987
- Fundamental
- Price
- IONS $32.26
- CMC $46.11
- Analyst Decision
- IONS Buy
- CMC Buy
- Analyst Count
- IONS 18
- CMC 7
- Target Price
- IONS $57.41
- CMC $60.33
- AVG Volume (30 Days)
- IONS 1.7M
- CMC 805.3K
- Earning Date
- IONS 04-30-2025
- CMC 06-20-2025
- Dividend Yield
- IONS N/A
- CMC 1.56%
- EPS Growth
- IONS N/A
- CMC N/A
- EPS
- IONS N/A
- CMC 0.63
- Revenue
- IONS $717,253,000.00
- CMC $7,738,612,000.00
- Revenue This Year
- IONS N/A
- CMC N/A
- Revenue Next Year
- IONS $27.39
- CMC $8.41
- P/E Ratio
- IONS N/A
- CMC $73.02
- Revenue Growth
- IONS N/A
- CMC N/A
- 52 Week Low
- IONS $23.95
- CMC $37.92
- 52 Week High
- IONS $52.34
- CMC $64.53
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- CMC 57.28
- Support Level
- IONS $31.66
- CMC $44.67
- Resistance Level
- IONS $33.98
- CMC $46.61
- Average True Range (ATR)
- IONS 1.30
- CMC 1.23
- MACD
- IONS 0.41
- CMC 0.38
- Stochastic Oscillator
- IONS 68.84
- CMC 83.84
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.